Legend Biotech (LEGN) Short term Debt (2021 - 2026)

Legend Biotech's (LEGN) quarterly Short term Debt came in at $266.0 million in Q1 2026, down 16.64% on a QoQ basis from $319.1 million in Q4 2025.

Legend Biotech (LEGN) Short term Debt (2021 - 2026) Analysis & Trends

Legend Biotech (LEGN) has 4 years of Short term Debt data on file, last reported at $266.0 million in Q1 2026.

Quarterly Short term Debt changed N/A year-over-year to $266.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $266.0 million (changed N/A YoY) and the FY2025 annual result came in at $319.1 million, changed N/A from the prior year.
Short term Debt eased to $266.0 million in Q1 2026, from $319.1 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $319.1 million in Q4 2025 to a low of $126.7 million in Q1 2022.
A 3-year average of $213.7 million and a median of $204.4 million in 2025 frame the typical range for Short term Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Legend Biotech	3.95 Bn	3.27 Bn	251.50 Mn

Download Data